Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period. by J Mark Ansermino (13958512)

Subjects:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya. by J Mark Ansermino (13958512)

Subjects:

Uganda: enrolment, time to IVA, mortality, admissions and readmissions. by J Mark Ansermino (13958512)

Subjects:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Kenya during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Bluetooth beacons with colour coded lanyards. by J Mark Ansermino (13958512)

Subjects:

Flow diagram of the Smart Triage multisite interventional study in Uganda and Kenya indicating the progress through study phases at each site. by J Mark Ansermino (13958512)

Subjects:

Mini-slump extension test cylinder. by Chenchen Luo (20649067)

“…However, as the oil shale residue content further increases, the hydration product gradually decreases, and the microstructure becomes poorer. Therefore, the optimal oil shale residue content is 20%. …”

Lymphocyte proliferation assay following combination therapy with NDV. by Hedieh Zargaran (21410233)

Tumor volume measurements. by Hedieh Zargaran (21410233)

Characterization of miRNA expression profiles and their potential targets upon Bz and Bz + PTX therapy in chronically infected mice. Relative expression was expressed as fold chang... by Glaucia Vilar-Pereira (686134)

IL-10 levels in tumor lysates post-treatment. by Hedieh Zargaran (21410233)

Metabolome data of the discovery cohort. by Feng Gao (3548)

Subjects:

The orthogonal projection to latent structure discriminant analysis (OPLS-DA) analysis of the three groups (OC vs HC, OC vs RC and RC vs HC) of the discovery cohort. by Feng Gao (3548)

Subjects:

S9 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects:

S3 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects:

Clinical characteristics of COVID-19 cases and healthy controls in the discovery cohort. by Feng Gao (3548)

Subjects:

S7 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects:

S2 Data - Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases by Feng Gao (3548)

Subjects:

Relative intensities of differential metabolites that may serve as potential metabolic biomarkers in Omicron variant cases. by Feng Gao (3548)

Subjects: